The National Health Council (NHC) appreciates the opportunity to comment on the Department of Health and Human Services’ (HHS) proposal to amend the safe harbor regulation concerning rebates and other […]
Letters + Comments
Committee on Health, Education, Labor, and Pensions (HELP) Request for Information on Lowering Health Care Costs
The National Health Council (NHC) appreciates the opportunity to submit comments in response to the request for information (RFI) from the Committee on Health, Education, Labor, and Pensions (HELP) on […]
Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2020
The National Health Council (NHC) appreciates the opportunity to comment on the Centers for Medicare & Medicaid Services’ (CMS’) Proposed Rule entitled, “HHS Notice of Benefit and Payment Parameters for […]
Institute for Clinical and Economic Review’s (ICER) Unsupported Price Increase Assessment
The National Health Council (NHC) is pleased to provide comments on the Institute for Clinical and Economic Review’s (ICER) solicitation for feedback on the Unsupported Price Increase Assessment draft protocol. […]
Food and Drug Administration’s (FDA) Framework for a Real-World Evidence Program; Availability
The National Health Council (NHC) is pleased to provide comments on the Food and Drug Administration’s (FDA) solicitation for feedback on FDA’s framework for a Real-World Evidence (RWE) Program, and […]
Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out of Pocket Expenses
The National Health Council (NHC) appreciates the opportunity to respond to the Centers for Medicare & Medicaid Services’ (CMS’) Proposed Rule entitled “Modernizing Part D and Medicare Advantage to Lower […]
Patient Engagement in Medical Device Clinical Trials Discussion Document
The National Health Council (NHC) is pleased to provide comments on the Food and Drug Administration (FDA)’s solicitation for feedback on patient engagement in medical device clinical trials, including the […]
Advance Notice of Proposed Rulemaking: International Price Index Model for Medicare Part B Drugs
The National Health Council (NHC) appreciates the opportunity to respond to the Centers for Medicare & Medicaid Services’ (CMS’) Advance Notice of Proposed Rulemaking entitled, “International Price Index Model for […]
Centers for Medicare & Medicaid Services’ (CMS’) State Relief and Empowerment Waivers
The National Health Council (NHC) submits this letter on the Centers for Medicare & Medicaid Services’ (CMS’) Guidance entitled “State Relief and Empowerment Waivers” and requests its withdrawal. The NHC […]
Patient-Focused Drug Development Guidance: Methods To Identify What Is Important to Patients and Select, Develop, or Modify Fit-for-Purpose Clinical Outcome Assessments
The National Health Council (NHC) is pleased to provide comments on the Food and Drug Administration’s (FDA) discussion documents related to Guidance 2: “Methods to Identify What is Important to […]